Ladha, Shafeeq

Barrow Neurological Institute

Citations 15

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | September 24, 2020 | Volume: 22 | Issue: 3-4 | Pages: 287-299

10.1080/21678421.2020.1822410 | PMID 32969758

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis

Science Translational Medicine | March 29, 2017 | Volume: 9 | Issue: 383 | Pages: No page available

10.1126/scitranslmed.aai7866 | PMID 28356511

Poly(GP) proteins are a promising pharmacodynamic marker for developing and testing therapeutics for treating C9ORF72 -associated amyotrophic lateral sclerosis.

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine

Muscle & Nerve | December 13, 2015 | Volume: 53 | Issue: 2 | Pages: 165-168

10.1002/mus.25009 | PMID 26662952

Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | July 8, 2013 | Volume: 14 | Issue: 7-8 | Pages: 632-634

10.3109/21678421.2013.808227 | PMID 23834161

Oncogenic osteomalacia: Muscular weakness and multiple fractures

Neurology | July 24, 2006 | Volume: 67 | Issue: 2 | Pages: 364-365

10.1212/01.wnl.0000225057.56863.33 | PMID 16864847